Interests of the Foundation

Our principal endeavors are directed toward improvement and development of methods for the detection, diagnosis and treatment of prostate cancer and the communication of this information. To this end, one goal is to educate men about the appropriate and inappropriate uses of the PSA test, which measures levels of prostate-specific antigen (PSA), a protein present in the blood.

This protein was identified as early as 1970 by Doctor Ablin (Ablin et al. J. Reprod. Fert., 22:573, 1970), but has only recently, following further studies, been utilized.  Doctor Ablin is one of the pioneers and early proponents of the use of cryosurgery, and the concept of cryoimmunotherapy, for the treatment of prostate cancer.

These are examples of the capabilities of the leadership of the Foundation.

With goals and interests directed more toward active research, rather than patient support, we nonetheless want you to know the facts about this disease.

All men should be informed of all their treatment options, not just those that special interest groups may want them to know, and to understand their respective expected risks and benefits. In this regard, no randomized clinical trial has been performed that has demonstrated one therapy to be superior to the others. Well-designed randomized, controlled clinical trials of treatment are now under way in the US and Europe, but the results will be unavailable for more than a decade.